Erasca Stock Gets Buy Rating: Analyst Sees Huge Potential in Cancer Drug
Stifel initiates Erasca coverage with Buy rating and $4 target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition.
NOTRELOAD AI
Critical Metals Secures $50M Investment for Greenland Rare Earth Project
Critical Metals Corp raises $50M through private investment to develop Tanbreez, one of world's largest rare earth deposits in Greenland, strengthening balance sheet.
Charles Schwab Crushes Q3 Earnings on Retail Investment Boom
Charles Schwab reports record Q3 earnings beating expectations with $134.4B in new assets and 30% trading growth driven by surging retail investor activity.
Snowflake Stock Jumps 6% on New Palantir AI Partnership
Partnership links their data platforms so businesses can create AI applications faster and easier.
JPMorgan Slashes Lithium Americas Rating After 200% Rally
JPMorgan downgrades Lithium Americas to Underweight with $5 target, citing overvaluation despite government investment. Stock faces 47% potential decline.
BofA Sees Big Potential in Vera Therapeutics' Autoimmune Drug
Bank of America starts coverage on Vera Therapeutics with Buy rating and $48 target, citing Atacicept's potential in multibillion-dollar autoimmune disease market.